The original success of the copyright undeniably revolutionized the drug landscape, but betting in companies primarily reliant on generic versions presents a complex picture. While early earnings were significant, the expiration of patents and the rise of less expensive alternatives have weakened market share. Thus, a thorough evaluation of present